Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
The small nucleic acid drugs developer has positioned itself as a leader in siRNA therapeutics, boasting one of the world’s largest pipelines of drugs using the technology Key Takeaways: Ribo…
Low margins, losses dog Ringpai as it eyes Hong Kong IPO
The company hopes to become Hong Kong’s first publicly listed pet hospital chain, hoping investors will overlook its weak performance metrics Key Takeaways: Ringpai has filed to list in Hong…
Move over, Hong Kong. Young Beijing Exchange becomes China’s new IPO hub
The bourse, launched in 2021 to help fund smaller tech startups, has hosted 38 IPOs this year, up more than 50% from 2024 Key Takeaways: Just four years after its…
Planter giant CSW extends roots to Hong Kong
The world’s largest producer of decorative plastic planters has applied for an IPO, boasting a mostly U.S. clientele that includes retailing giants like Lowe’s, Walmart and Costco Key Takeaways: CSW…
Soaped up by its U.S. success, COL Group sets sail for Hong Kong
The company says it plans to list in Hong Kong, basking in the limelight of strong demand from American viewers for its over-the-top Chinese-style soap operas Key Takeaways: COL Group,…
Zeekr drives off Wall Street, heralding chilly year ahead for U.S. Chinese listings
Trading of the EV maker’s shares was suspended on Dec. 22, after investors approved a plan by parent Geely to privatize the company less than two years after its IPO…
Hong Kong chip frenzy enters AI lane with Iluvatar IPO
The maker of general purpose GPUs used in AI computing has made its first public filing and passed its listing hearing for a Hong Kong IPO that could raise around…
Recent Articles
RELATED ARTICLES
-
BRIEF: Leading RNA drug developer Ribo passes Hong Kong listing hearing, kicking off IPO
- Armed with AstraZeneca deal, Eccogene files for Hong Kong IPO
- Obesity drug maker Sciwind targets IPO, with heavyweight backers
- Ming Yu seeks a share of the drug sector limelight
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK
- Genuine Biotech takes third shot at IPO as financial pressures mount
-
Hengrui Pharma targets obesity drug launch after test success
1278.HK600276.SHG
